Our primary mission is to accelerate the development of new treatments for families with a TNPO2-mutation diagnosis.
Our secondary mission is to turn our journey into a path that other monogenic, toxic-gain-of-function mutation patients can follow.
Our secondary mission is to turn our journey into a path that other monogenic, toxic-gain-of-function mutation patients can follow.